Botanix Pharma has updated its corporate governance policies, including whistleblower and anti-bribery measures, and set measurable objectives for gender diversity on its board. The company disclosed its updated policies and progress towards achieving gender diversity in its latest announcement.
Material actions and disclosures
Botanix Pharma has disclosed its whistleblower policy and anti-bribery and corruption policy on its website. The company ensures that the board or a committee of the board is informed of any material incidents or breaches reported under these policies.
The company has also set a measurable objective for achieving gender diversity in the composition of its board, aiming for at least 30% of its directors to be of each gender by no later than 30 June 2026. The current proportion of women on the board is 20%, with the company looking to improve its female representation.
Forward commitments
Botanix Pharma aims to continue reviewing its risk management framework annually and disclosing the results of these reviews. The company also plans to maintain its commitment to corporate governance by ensuring that all substantive resolutions at shareholder meetings are decided by a poll rather than a show of hands.
The company will continue to evaluate the performance of the board, its committees, and individual directors periodically, as outlined in its Performance Evaluation Policy.
Botanix Pharma will also continue to provide security holders with the option to receive communications from the entity and its security registry electronically, in line with its Shareholder Communication Policy.
These updates reflect Botanix Pharma’s ongoing commitment to enhancing its corporate governance and diversity practices.